{"id":"W4310753899","doi":"10.1016/j.annonc.2022.10.356","title":"319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Crizotinib; Alectinib; Medicine; Refractory (planetary science); Randomized controlled trial; Internal medicine; Oncology; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001596984,0.002066805,0.003265473,0.0004242601,0.0004735468,0.001996664,0.001090863,0.001749562,0.008856625],"category_scores_gemma":[0.001664301,0.0009078835,0.002989791,0.0004479256,0.001457339,0.001726702,0.0006225666,0.005483054,0.001912325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001160481,"about_ca_system_score_gemma":0.001080031,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001683516,"about_ca_topic_score_gemma":0.003940352,"domain_scores_codex":[0.9993148,0.0003324831,0.00004163952,0.0001204918,0.00003880919,0.0001517266],"domain_scores_gemma":[0.999339,0.0001508846,0.000137963,0.0000667627,0.00003696451,0.0002684097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9864292,0.001469669,0.0005129972,0.000330438,0.001304959,0.00003088794,0.00002376373,0.0003608201,0.001621213,0.0001486373,0.0008218146,0.006945653],"study_design_scores_gemma":[0.9779838,0.01836306,0.001173834,0.00002734151,0.0009525148,0.00003071785,0.00002214225,0.0004991071,0.0001928418,0.0001979893,0.0005396019,0.00001707062],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814889,0.007077169,0.0006030521,0.001830077,0.001462286,0.001717759,0.001543727,0.0002720197,0.004005018],"genre_scores_gemma":[0.9883492,0.002356828,0.0007729368,0.001404164,0.0005981573,0.001369521,0.001585197,0.00005124779,0.003512708],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008856625,"threshold_uncertainty_score":0.02962834,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0517741438347148,"score_gpt":0.436796084221702,"score_spread":0.3850219403869872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}